| Dimension | Scoring Notes | Score |
|---|---|---|
| Study Design | Decades of regulatory-grade Phase III RCTs underpin the approved indications (pediatric and adult GH deficiency, Turner syndrome, Prader-Willi, chronic kidney disease, SHOX deficiency, HIV wasting). Among the most rigorously trialed compounds in the catalog. The methodology behind the approved uses is excellent; the healthy-adult anti-aging literature is much sparser and lower-powered. |
24 / 25 |
| Sample Size | Cumulative enrollment across approval trials, 35+ years of post-marketing surveillance, and large international registries (KIGS pediatric, KIMS adult) runs well into the tens of thousands of patients. |
19 / 20 |
| Replication | Core findings replicated independently across endocrinology centers worldwide over more than three decades. Replication of the anti-aging claims is weaker and several independent reviews have tempered the original Rudman (1990) findings. |
18 / 20 |
| Journal Impact Factor | Primary literature appears in NEJM, The Lancet, JCEM, and Annals of Internal Medicine, top-tier general medicine and specialty endocrinology journals. |
13 / 15 |
| Funding Independence | Development trials were industry-sponsored (Genentech, Lilly, Pfizer, Novo Nordisk). This is offset by a substantial independent academic, NIH, and registry literature, including independent reviews that critically reassessed the anti-aging claims rather than promoting them. |
7 / 10 |
| Population Diversity | Studied across pediatric and adult cohorts, both sexes, multiple distinct clinical populations, and many countries. Marked down slightly because healthy-aging cohorts are narrower and older-male-skewed. |
4 / 5 |
| Researcher h-Index | Primary investigators are leading clinical endocrinologists with very high citation profiles in major biomedical databases. |
5 / 5 |